Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
GlycoMimetics (GLYC) has issued an update.
GlycoMimetics, Inc. announced significant findings from its Phase 3 trial of uproleselan, targeting relapsed/refractory acute myeloid leukemia, and held a live webcast to discuss these outcomes. While detailed results were shared, this information is for disclosure purposes and will not be considered officially filed or integrated into prior or future securities filings, unless explicitly stated.
Find detailed analytics on GLYC stock on TipRanks’ Stock Analysis page.
